Compare BLBD & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLBD | TSHA |
|---|---|---|
| Founded | 1927 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | N/A | 2020 |
| Metric | BLBD | TSHA |
|---|---|---|
| Price | $49.70 | $5.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $64.60 | $10.56 |
| AVG Volume (30 Days) | 460.2K | ★ 2.5M |
| Earning Date | 02-04-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.79 | N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $1,480,099,000.00 | $6,310,000.00 |
| Revenue This Year | $4.86 | N/A |
| Revenue Next Year | $3.41 | N/A |
| P/E Ratio | $12.64 | ★ N/A |
| Revenue Growth | ★ 9.87 | N/A |
| 52 Week Low | $30.04 | $1.05 |
| 52 Week High | $61.95 | $6.02 |
| Indicator | BLBD | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 49.78 |
| Support Level | $47.43 | $4.40 |
| Resistance Level | $50.34 | $5.17 |
| Average True Range (ATR) | 1.41 | 0.36 |
| MACD | 0.25 | -0.06 |
| Stochastic Oscillator | 81.82 | 50.77 |
Blue Bird Corp is an American bus manufacturing company. It is an independent designer and manufacturer of school buses. The company operates in two segments; the Bus segment which involves the design, engineering, manufacture, and sales of school buses and extended warranties; and the Parts segment which includes the sales of replacement bus parts. Geographically, the company generates a majority of its revenue from its customers in the United States and the rest from Canada and Rest of the world.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.